Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
172 Clinical Trials near Gig Harbor, WA
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerMezigdomide + Carfilzomib + Dexamethasone for Multiple Myeloma
Tacoma, Washington
This trial is testing a new drug called Mezigdomide combined with two other drugs to treat patients whose blood cancer has come back or not responded to previous treatments. The new drug aims to stop cancer cells from growing and spreading.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Allogeneic Transplant, Recent Autologous Transplant, Others
Must Not Be Taking:Mezigdomide, Carfilzomib
525 Participants Needed
Tec-DR and Tal-DR for Multiple Myeloma
Tacoma, Washington
This trial is testing two new drug combinations to see if they work better than the current standard treatment for multiple myeloma. The new treatments aim to help the immune system find and destroy cancer cells more effectively.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Stroke, Seizure, Allergies, Others
Must Not Be Taking:Corticosteroids
1590 Participants Needed
Gedatolisib + Fulvestrant +/- Palbociclib for Advanced Breast Cancer
Tacoma, Washington
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Diabetes, Brain Metastases, Cardiovascular, Others
Must Be Taking:LHRH Agonists
701 Participants Needed
Remternetug for Alzheimer's Disease
Tacoma, Washington
This trial tests remternetug, a drug given by injection or IV, in people with early Alzheimer's disease. It aims to find out if the drug is safe and can help improve symptoms or slow down the disease.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60 - 85
Key Eligibility Criteria
Disqualifiers:Unstable Illnesses, Cancer, Psychiatric Diagnosis, Others
Must Not Be Taking:Anti-amyloid Immunotherapy
1667 Participants Needed
Somapacitan vs Norditropin for Growth Disorders
Tacoma, Washington
This trial compares two growth hormone treatments for children with growth issues. Somapacitan is a new treatment, while Norditropin® is an existing treatment. The study aims to find out which treatment helps these children grow better. Somapacitan is a long-acting growth hormone derivative in development for treatment of GH deficiency.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:2 - 10
Key Eligibility Criteria
Disqualifiers:ADHD, Malignancy, Hepatitis B/C, Others
Must Not Be Taking:Systemic Corticosteroids, Inhaled Glucocorticoids, Methylphenidate, Sex Hormones
399 Participants Needed
Giredestrant + Everolimus for Advanced or Metastatic Breast Cancer
Tacoma, Washington
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Chemotherapy, CNS Metastases, Cardiac Disease, Others
Must Be Taking:LHRH Agonists
373 Participants Needed
This trial tests a combination of two drugs, pembrolizumab and vibostolimab, along with standard chemotherapy and radiation in patients with advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can better control the disease and improve survival compared to another drug, durvalumab. These drugs help the immune system attack cancer cells more effectively.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:SCLC, Immunodeficiency, Autoimmune, Others
Must Not Be Taking:Steroids, Immunosuppressants, NSAIDs, Others
611 Participants Needed
Durvalumab + Oleclumab/Monalizumab for Lung Cancer
Tacoma, Washington
This trial is testing two drug combinations to help the immune system fight advanced lung cancer that can't be surgically removed. The patients have already had previous treatment without their disease getting worse. The drugs aim to boost the immune response to better identify and kill cancer cells.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Pneumonitis, Autoimmune Disorders, Others
Must Not Be Taking:Immunosuppressants
1027 Participants Needed
Obicetrapib for Cardiovascular Disease
Tacoma, Washington
This trial is testing a new medication called Obicetrapib to help people with heart disease who still have high cholesterol despite taking strong treatments. The goal is to see if this medication can lower their risk of heart attacks, strokes, and other serious heart problems by reducing bad cholesterol levels.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Heart Failure, MI, Stroke, Hypertension, Others
Must Be Taking:Lipid-modifying Therapy
9541 Participants Needed
Metreleptin for Partial Lipodystrophy
Tacoma, Washington
This trial tests the safety and effectiveness of daily injections of metreleptin for people with Partial Lipodystrophy. The treatment aims to replace a missing hormone to help their bodies manage fat and sugar levels better. Metreleptin is approved by the United States Food and Drug Administration for the treatment of generalized forms of lipodystrophy and has shown improvement in many patients.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12+
Key Eligibility Criteria
Disqualifiers:Previous Metreleptin, High Leptin, APL, Others
69 Participants Needed
Lurbinectedin +/- Irinotecan for Small Cell Lung Cancer
Tacoma, Washington
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Heart Disease, Liver Disease, HIV, Others
Must Not Be Taking:Topoisomerase Inhibitors
705 Participants Needed
Trastuzumab Deruxtecan for Early Stage Breast Cancer
Tacoma, Washington
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Invasive Breast Cancer, Stage IV, ILD/pneumonitis, Others
Must Not Be Taking:Anthracyclines, Cyclophosphamide, Taxanes
927 Participants Needed
Setmelanotide for Obesity
Tacoma, Washington
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:
* POMC or PCSK1 (Sub-study 035a)
* LEPR (Sub-study 035b)
* SRC1 (Sub-study 035c)
* SH2B1 (Sub-study 035d)
The objectives and endpoints are identical for these sub-studies.
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 65
Key Eligibility Criteria
Disqualifiers:Psychiatric Disorders, Suicidal Ideation, Pulmonary, Cardiac, Endocrine, Others
400 Participants Needed
Oral Ozanimod for Pediatric Ulcerative Colitis
Tacoma, Washington
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:2 - 17
Key Eligibility Criteria
Disqualifiers:Crohn's Disease, Immunodeficiency, Others
120 Participants Needed
Baricitinib for Pediatric COVID-19
Tacoma, Washington
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 18
Key Eligibility Criteria
Disqualifiers:Active TB, Active Malignancy, VTE History, Others
Must Not Be Taking:Biologics, Immunosuppressants, OAT3 Inhibitors
24 Participants Needed
Cenobamate for Epilepsy
Tacoma, Washington
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:2 - 18
Key Eligibility Criteria
Disqualifiers:Pregnancy, Pseudo-seizures, Psychiatric Disorders, Others
Must Be Taking:Antiepileptic Drugs
140 Participants Needed
Fenfluramine for CDKL5 Deficiency Disorder
Tacoma, Washington
This trial tests ZX008, a medication added to current treatments, in children and adults with CDD who have uncontrolled seizures. The goal is to see if ZX008 can help better control their seizures.
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:1 - 35
Key Eligibility Criteria
Disqualifiers:Pulmonary Hypertension, Cardiovascular Disease, Others
Must Be Taking:Antiseizure Treatments
87 Participants Needed
RSVpreF Vaccine for Bronchitis
Tacoma, Washington
Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults:
* At a dose of 120µg.
* In adults 60 years of age and older.
* The duration of the study for each participant will be up to approximately 24 months.
* The study will be conducted in the United States, Canada, Netherlands, Finland, Argentina, Japan and South Africa.
Substudy A: This study is an extension of the efficacy study and was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 2 years:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in the United States and Argentina.
Substudy B: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of approximately 1 year:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 18 months.
* The study will be conducted in Argentina.
Substudy C: This study was designed to evaluate the safety and immunogenicity of a second dose of RSVpreF when administered after a dosing interval of either 3 or 4 years:
* At a dose of 120µg (as studied in the Phase 3 Efficacy Study)
* Participants will receive either placebo or a second dose of RSVpreF approximately 3 or 4 years after receiving the initial dose of RSVpreF in the main efficacy study.
* Blood samples will be collected for antibody testing.
* The duration of the study for each participant will be up to approximately 24 months.
* The study will be conducted in the United States and Canada.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:60+
Key Eligibility Criteria
Disqualifiers:Metastatic Malignancy, End-stage Renal Disease, Unstable Cardiac Disease, Immunodeficiency, Others
Must Not Be Taking:Immunosuppressants, Corticosteroids
38861 Participants Needed
Inclisiran for Cardiovascular Disease
Tacoma, Washington
This trial is testing inclisiran, an injectable drug, on people with heart disease who are already on strong cholesterol-lowering medications. The goal is to see if inclisiran can further reduce the risk of heart attacks and strokes by lowering bad cholesterol levels. Participants will receive the injection periodically. Inclisiran works by significantly reducing bad cholesterol levels.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:40+
Key Eligibility Criteria
Disqualifiers:Heart Failure, Active Liver Disease, Others
Must Be Taking:High-intensity Statins
17004 Participants Needed
Donanemab for Alzheimer's Disease
Tacoma, Washington
This trial is testing donanemab, a medication aimed at helping people with Alzheimer's Disease by removing harmful protein clumps from their brains. Donanemab has shown promise in reducing these harmful proteins in Alzheimer's disease.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:65 - 80
Key Eligibility Criteria
Disqualifiers:Mild Cognitive Impairment, Dementia, Cancer, Others
Must Not Be Taking:Cognitive Enhancers
2996 Participants Needed
Why Other Patients Applied
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."
WR
Obesity PatientAge: 58
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
Tivozanib + Nivolumab for Kidney Cancer
Tacoma, Washington
This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Uncontrolled Hypertension, Others
Must Be Taking:Immune Checkpoint Inhibitors
343 Participants Needed
AZD9833 + CDK4/6 Inhibitor for Breast Cancer
Tacoma, Washington
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:CNS Metastases, Severe Heart Disease, Others
Must Be Taking:CDK4/6 Inhibitors, AIs
315 Participants Needed
Know someone looking for new options?
Spread the word